Epstein-Barr Virus Nuclear Antigen 3A Promotes Cellular Proliferation by Repression of the Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1

PLoS Pathogens

Volumn 10, Issue 10, 2014, Pages

  Tursiella, Melissa L ^a   Bowman, Emily R ^a   Wanzeck, Keith C ^b   Throm, Robert E ^b   Liao, Jason ^a   Zhu, Junjia ^a   Sample, Clare E ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPSTEIN BARR VIRUS ANTIGEN 3A; EPSTEIN BARR VIRUS ANTIGEN 3C; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GREEN FLUORESCENT PROTEIN; LAMIN B; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; PROTEIN P21; PROTEIN P53; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; CYCLIN DEPENDENT KINASE; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; LYMPHOCRYPTOVIRUS NUCLEAR ANTIGEN 3A;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS ASSAY; ARTICLE; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL LYSATE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; LYMPHOBLASTOID CELL LINE; MCF 7 CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS REGULATION; RECOMBINANT PLASMID; SAOS 2 CELL LINE; UPREGULATION; XENOGRAFT; ANIMAL; BURKITT LYMPHOMA; CELL LINE; GENETICS; METABOLISM; PHYSIOLOGY; VIROLOGY;

HUMAN HERPESVIRUS 4;

ANIMALS; ANTIGENS, VIRAL; BURKITT LYMPHOMA; CELL LINE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HUMANS; MICE;

EID: 84908339066     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004415     Document Type: Article

References (104)

1. Kieff E, Rickinson A (2006) Epstein-Barr Virus and Its Replication. In: Knipe D, Howley P, editors. Fields Virology. Fifth Edition ed. Philadelphia, PA: Lippincott Williams & Wilkins. pp. 2626.
2. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, et al. (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6: 2743–2751.
3. Woisetschlaeger M, Yandava CN, Furmanski LA, Strominger JL, Speck SH, (1990) Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc Natl Acad Sci U S A 87: 1725–1729.
4. Sample J, Hummel M, Braun D, Birkenbach M, Kieff E, (1986) Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci U S A 83: 5096–5100.
5. Bodescot M, Perricaudet M, Farrell PJ, (1987) A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol 61: 3424–3430.
6. Schaefer BC, Strominger JL, Speck SH, (1995) Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci U S A 92: 10565–10569.
7. Nonkwelo C, Skinner J, Bell A, Rickinson A, Sample J, (1996) Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 70: 623–627.
8. Magrath IT, (1991) African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 13: 222–246.
9. Rowe M, Kelly GL, Bell AI, Rickinson AB, (2009) Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 19: 377–388.
10. Kelly G, Bell A, Rickinson A, (2002) Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8: 1098–1104.
11. Leao M, Anderton E, Wade M, Meekings K, Allday MJ, (2007) Epstein-Barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J Virol 81: 248–260.
12. Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, et al. (2009) An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog 5: e1000341.
13. Austin PJ, Flemington E, Yandava CN, Strominger JL, Speck SH, (1988) Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. Proc Natl Acad Sci U S A 85: 3678–3682.
14. Pearson GR, Luka J, Petti L, Sample J, Birkenbach M, et al. (1987) Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology 160: 151–161.
15. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424–2433.
16. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, et al. (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 95: 8292–8297.
17. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713–723.
18. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, et al. (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001–5014.
19. Zhang Y, Xiong Y, Yarbrough WG, (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734.
20. Sample JT, Ruf IK (2006) Burkitt Lymphoma In: Tselis A, Johnson HB, editor. Epstein-Barr Virus. New York, NY: Informa Healthcare. pp. 187–222.
21. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL, (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658–2669.
22. Anderton E, Yee J, Smith P, Crook T, White RE, et al. (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27: 421–433.
23. Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB, (2006) Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A 103: 14935–14940.
24. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, et al. (1984) DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310: 207–211.
25. Petti L, Sample J, Wang F, Kieff E, (1988) A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol 62: 1330–1338.
26. Ricksten A, Kallin B, Alexander H, Dillner J, Fahraeus R, et al. (1988) BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A 85: 995–999.
27. Tomkinson B, Kieff E, (1992) Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol 66: 2893–2903.
28. Tomkinson B, Robertson E, Kieff E, (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67: 2014–2025.
29. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, et al. (2006) Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci U S A 103: 19500–19505.
30. Maruo S, Johannsen E, Illanes D, Cooper A, Kieff E, (2003) Epstein-Barr Virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth. J Virol 77: 10437–10447.
31. Le Roux A, Kerdiles B, Walls D, Dedieu JF, Perricaudet M, (1994) The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology 205: 596–602.
32. Johannsen E, Miller CL, Grossman SR, Kieff E, (1996) EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes. J Virol 70: 4179–4183.
33. Zhao B, Marshall DR, Sample CE, (1996) A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa. J Virol 70: 4228–4236.
34. Jimenez-Ramirez C, Brooks AJ, Forshell LP, Yakimchuk K, Zhao B, et al. (2006) Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter. J Virol 80: 11200–11208.
35. Touitou R, Hickabottom M, Parker G, Crook T, Allday MJ, (2001) Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Virol 75: 7749–7755.
36. Hickabottom M, Parker GA, Freemont P, Crook T, Allday MJ, (2002) Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J Biol Chem 277: 47197–47204.
37. Zhao B, Sample CE, (2000) Epstein-Barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site. J Virol 74: 5151–5160.
38. Krauer KG, Burgess A, Buck M, Flanagan J, Sculley TB, et al. (2004) The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 23: 1342–1353.
39. Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, et al. (2009) Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog 5: e1000506.
40. Clybouw C, McHichi B, Mouhamad S, Auffredou MT, Bourgeade MF, et al. (2005) EBV infection of human B lymphocytes leads to down-regulation of Bim expression: relationship to resistance to apoptosis. J Immunol 175: 2968–2973.
41. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, et al. (2011) Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 108: 1919–1924.
42. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ, (2010) Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6: e1000951.
43. Zhao B, Mar JC, Maruo S, Lee S, Gewurz BE, et al. (2011) Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci U S A 108: 337–342.
44. Skalska L, White RE, Parker GA, Sinclair AJ, Paschos K, et al. (2013) Induction of p16(INK4a) Is the Major Barrier to Proliferation when Epstein-Barr Virus (EBV) Transforms Primary B Cells into Lymphoblastoid Cell Lines. PLoS Pathog 9: e1003187.
45. Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, et al. (1999) The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 73: 4481–4484.
46. Caldwell RG, Brown RC, Longnecker R, (2000) Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 74: 1101–1113.
47. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R, (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9: 405–411.
48. Knutson JC, (1990) The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J Virol 64: 2530–2536.
49. Peng M, Lundgren E, (1992) Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 7: 1775–1782.
50. Ohtani N, Brennan P, Gaubatz S, Sanij E, Hertzog P, et al. (2003) Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5. J Cell Biol 162: 173–183.
51. Rowe M, Peng-Pilon M, Huen DS, Hardy R, Croom-Carter D, et al. (1994) Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 68: 5602–5612.
52. Watanabe A, Maruo S, Ito T, Ito M, Katsumura KR, et al. (2010) Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1. J Virol 84: 2893–2901.
53. Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, et al. (1999) Epstein-Barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol 19: 1651–1660.
54. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K, (1994) Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 68: 6069–6073.
55. Rao L, Perez D, White E, (1996) Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol 135: 1441–1455.
56. Oberhammer FA, Hochegger K, Froschl G, Tiefenbacher R, Pavelka M, (1994) Chromatin condensation during apoptosis is accompanied by degradation of lamin A+B, without enhanced activation of cdc2 kinase. J Cell Biol 126: 827–837.
57. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC, (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346–347.
58. Buendia B, Santa-Maria A, Courvalin JC, (1999) Caspase-dependent proteolysis of integral and peripheral proteins of nuclear membranes and nuclear pore complex proteins during apoptosis. J Cell Sci 112 (Pt 11) 1743–1753.
59. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, et al. (1982) Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 79: 7824–7827.
60. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, et al. (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 79: 7837–7841.
61. Askew DS, Ashmun RA, Simmons BC, Cleveland JL, (1991) Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915–1922.
62. Chencheri SC, Tursiella ML, Sample CE, (2014) Epstein-Barr virus EBNA-3C contributes to apoptotic resistance but not proliferation of Wp-R BL cells. In Press
63. Barak Y, Juven T, Haffner R, Oren M, (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461–468.
64. Nakano K, Vousden KH, (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683–694.
65. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, et al. (1990) Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes. Cell Growth Differ 1: 571–580.
66. Pokrovskaja K, Ehlin-Henriksson B, Bartkova J, Bartek J, Scuderi R, et al. (1996) Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines. Cell Growth Differ 7: 1723–1732.
67. Sherr CJ, Roberts JM, (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501–1512.
68. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704.
69. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ, (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816.
70. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, et al. (1995) Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6: 387–400.
71. Gu Y, Turck CW, Morgan DO, (1993) Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366: 707–710.
72. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
73. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P, (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675–684.
74. Cayrol C, Flemington EK, (1996) The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J 15: 2748–2759.
75. Countryman J, Jenson H, Seibl R, Wolf H, Miller G, (1987) Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol 61: 3672–3679.
76. Rooney CM, Rowe DT, Ragot T, Farrell PJ, (1989) The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol 63: 3109–3116.
77. Jepsen JS, Pfundheller HM, Lykkesfeldt AE, (2004) Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides 14: 147–156.
78. Vereide DT, Sugden B, (2011) Lymphomas differ in their dependence on Epstein-Barr virus. Blood 117: 1977–1985.
79. Magrath I, (1990) The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 55: 133–270.
80. Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ, (2012) BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res 40: 7233–7246.
81. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, et al. (2009) Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5: e1000492.
82. Happo L, Cragg MS, Phipson B, Haga JM, Jansen ES, et al. (2010) Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 116: 5256–5267.
83. Knight JS, Sharma N, Robertson ES, (2005) Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A 102: 18562–18566.
84. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, et al. (1998) p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 91: 1680–1687.
85. Cannell EJ, Farrell PJ, Sinclair AJ, (1996) Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells. Oncogene 13: 1413–1421.
86. Galaktionov K, Chen X, Beach D, (1996) Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382: 511–517.
87. Sinclair AJ, Palmero I, Peters G, Farrell PJ, (1994) EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 13: 3321–3328.
88. Broude EV, Swift ME, Vivo C, Chang BD, Davis BM, et al. (2007) p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene 26: 6954–6958.
89. Sdek P, Ying H, Zheng H, Margulis A, Tang X, et al. (2004) The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J Biol Chem 279: 53317–53322.
90. Sdek P, Ying H, Chang DL, Qiu W, Zheng H, et al. (2005) MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20: 699–708.
91. Chang BD, Watanabe K, Broude EV, Fang J, Poole JC, et al. (2000) Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A 97: 4291–4296.
92. Janicke RU, Walker PA, Lin XY, Porter AG, (1996) Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 15: 6969–6978.
93. Zhang H, Hannon GJ, Beach D, (1994) p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8: 1750–1758.
94. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, et al. (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847–862.
95. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, et al. (1999) The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18: 1571–1583.
96. Hammerschmidt W, Sugden B, (1989) Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340: 393–397.
97. Cohen JI, Wang F, Kieff E, (1991) Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 65: 2545–2554.
98. Cohen JI, Wang F, Mannick J, Kieff E, (1989) Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A 86: 9558–9562.
99. Allday MJ, Sinclair A, Parker G, Crawford DH, Farrell PJ, (1995) Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J 14: 1382–1391.
100. O'Nions J, Allday MJ, (2003) Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2. Oncogene 22: 7181–7191.
101. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, et al. (2009) Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 83: 4652–4669.
102. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, et al. (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A 99: 5515–5520.
103. Gorska A, Swiatkowska A, Dutkiewicz M, Ciesiolka J, (2013) Modulation of p53 expression using antisense oligonucleotides complementary to the 5′-terminal region of p53 mRNA in vitro and in the living cells. PLoS One 8: e78863.
104. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.